A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma
CompletedOBSERVATIONAL
Enrollment
713
Participants
Timeline
Start Date
July 2, 2018
Primary Completion Date
February 20, 2020
Study Completion Date
February 20, 2020
Conditions
Carcinoma, Hepatocellular
Interventions
DRUG
Lenvatinib
Lenvatinib capsule
Trial Locations (2)
Unknown
Eisai trial site 1, Osaka
Eisai trial site 2, Tokyo
All Listed Sponsors
lead
Eisai Inc.
INDUSTRY
NCT03663114 - A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter